Nexus Pharmaceuticals Seeks New Trial Following Exela's Clearance in $89M IP Case

By Editorial Team

Nexus Pharmaceuticals has filed a request with a Delaware federal judge for a new trial regarding its patent infringement allegations against Exela Pharma Sciences. This move comes after a jury ruled in September to clear Exela of the claims, a decision Nexus believes was made "against the great weight of evidence."

The case revolves around patent infringement claims related to compositions comprising ephedrine or an ephedrine salt, along with methods of making and using the same. The patents in question are 11,464,752, 11,426,369, and 11,571,398.

Legal representation in the case includes law firms ArentFox Schiff, Fish & Richardson, and Richards Layton. The involved companies are Exela Pharma Sciences LLC and Nexus Pharmaceuticals Inc. The matter is being heard in the U.S. District Court for the District of Delaware, with involvement from the U.S. Patent and Trademark Office.

Nexus Pharmaceuticals' motion for a new trial aims to challenge the jury's decision and present additional evidence to support its patent infringement claims against Exela Pharma Sciences. The outcome of this request could potentially impact the $89 million intellectual property case.